CA
IKT icon

Clearstead Advisors’s Inhibikase Therapeutics IKT Stock Holding History

Clearstead Advisors’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13 Buy
+6
New +$11 ﹤0.01% 3610

Other funds holding IKT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
AHL
Abel Hall LLC Baton Rouge, Louisiana $579M AUM 54.21% 1-Year Est. Return

Clearstead Advisors's IKT Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Inhibikase Therapeutics (IKT) in Q2 2026: 6 shares worth $13. The stake represents ﹤0.01% of the portfolio and ranks #3610 among its holdings.

25 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Clearstead Advisors held 6 shares of Inhibikase Therapeutics worth $13 as of Q2 2026.
  • Inhibikase Therapeutics was a new Clearstead Advisors position in Q2 2026.
  • Inhibikase Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3610 holding.
  • 25 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.